Targeted therapy and immunotherapy of esophageal cancer
10.3760/cma.j.cn371439-20210520-00043
- VernacularTitle:食管癌的靶向治疗及免疫治疗
- Author:
Jianfeng ZHOU
1
;
Tiejun WANG
Author Information
1. 吉林大学第二医院放疗科，长春 130000
- Keywords:
Esophageal neoplasms;
Molecular targeted therapy;
Immunotherapy
- From:
Journal of International Oncology
2022;49(4):237-242
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal cancer is a complex digestive tract cancer. Currently, the study of radiotherapy and chemotherapy for non-surgical esophageal cancer has reached the bottleneck. In recent years, with the in-depth study of tumor signal pathway related targets and immunotherapy, tumor treatment methods are becoming more and more diversified. At present, research shows that a variety of gene targets and immune receptors are related to esophageal cancer, including epidermal growth factor receptor, vascular endothelial growth factor, human epidermal growth factor receptor 2, programmed death-1/programmed death ligand-1, etc. In addition, tumor vaccine and adoptive cell therapy are also being studied. These factors contribute to the individualized and accurate treatment of esophageal cancer and improve survival rate and local control rate.
